Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | MPO | P05164 | 7/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.52 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30877828 | 0.86 | OPRM1 (0.67) | GPR84SLC6A4MPOKMT2AHTR2A | |
| SCHEMBL29206498 | 0.86 | OPRM1 (0.67) | GPR84SLC6A4MPOKMT2AHTR2A | |
| SCHEMBL24694004 | 0.81 | OPRM1 (0.65) | GPR84SLC6A4MAPK1MPOKMT2A | |
| SCHEMBL26996488 | 0.78 | SLC6A4 (0.83) | GPR84SLC6A4MAPK1MPOKMT2A | |
| SCHEMBL14036644 | 0.78 | MPO (0.72) | GPR84SLC6A4MPOKMT2AHTR2A | |
| SCHEMBL8266302 | 0.78 | HTT (0.85) | GPR84SLC6A4MAPK1LMNAHTT | |
| SCHEMBL10119871 | 0.76 | SLC6A4 (0.72) | GPR84SLC6A4MAPK1MPOHTR2A | |
| SCHEMBL7479891 | 0.76 | SLC6A4 (0.62) | SLC6A4HTR2AHTR1AOPRM1OPRL1 | |
| SCHEMBL13973054 | 0.76 | MPO (0.74) | GPR84SLC6A4MPOHTR2ATRPM8 | |
| SCHEMBL18383118 | 0.76 | GPR84 (1.00) | GPR84SLC6A4MPOKMT2AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975252-B2 | Morpholine derivative | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-03-10 | — | — | US | disclosed |
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | REN, AGTR1, AGTR2 | GPR84 2282/4885SLC6A4 1492/4885MAPK1 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.